Manuel Pombo‐Suárez

1.6k total citations
28 papers, 809 citations indexed

About

Manuel Pombo‐Suárez is a scholar working on Rheumatology, Immunology and Molecular Biology. According to data from OpenAlex, Manuel Pombo‐Suárez has authored 28 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 6 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Manuel Pombo‐Suárez's work include Rheumatoid Arthritis Research and Therapies (16 papers), Osteoarthritis Treatment and Mechanisms (10 papers) and Spondyloarthritis Studies and Treatments (6 papers). Manuel Pombo‐Suárez is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Osteoarthritis Treatment and Mechanisms (10 papers) and Spondyloarthritis Studies and Treatments (6 papers). Manuel Pombo‐Suárez collaborates with scholars based in Spain, Switzerland and Italy. Manuel Pombo‐Suárez's co-authors include Juan J. Gómez‐Reino, Antonio González, Julio A. Rodriguez‐Lopez, John Loughlin, James M. Wilkins, Kay Chapman, Lorraine Southam, Manuel Calaza, Sarah Snelling and Inken Lorenzen and has published in prestigious journals such as Pain, Human Molecular Genetics and Frontiers in Immunology.

In The Last Decade

Manuel Pombo‐Suárez

26 papers receiving 792 citations

Peers

Countries citing papers authored by Manuel Pombo‐Suárez

Since Specialization

Citations

This map shows the geographic impact of Manuel Pombo‐Suárez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Pombo‐Suárez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Pombo‐Suárez more than expected).

Fields of papers citing papers by Manuel Pombo‐Suárez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Pombo‐Suárez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Pombo‐Suárez. The network helps show where Manuel Pombo‐Suárez may publish in the future.

Co-authorship network of co-authors of Manuel Pombo‐Suárez

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Pombo‐Suárez. A scholar is included among the top collaborators of Manuel Pombo‐Suárez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Pombo‐Suárez. Manuel Pombo‐Suárez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry 2024 ·Arthritis Research & Therapy ·J. Calvo-Gutiérrez, Clementina López‐Medina, (unknown), Alejandro Escudero‐Contreras, R. Ortega Castro, Lourdes Ladehesa-Pineda, Cristina Campos, (unknown), (unknown), (unknown), (unknown), Manuel Pombo‐Suárez, (unknown), Fernando Sánchez‐Alonso, Isabel Castrejón	3
2	Early identification of golimumab-treated patients with higher likelihood of long-term retention 2024 ·Frontiers in Immunology ·(unknown), Enrique González‐Dávila, (unknown), Luis Cea‐Calvo, Manuel Pombo‐Suárez, Fernando Sánchez‐Alonso, Isabel Castrejón, Federico Díaz‐González	2
3	POS1073 IMPACT OF COMORBIDITIES ON THE FIRST BDMARD EFFECTIVENESS AND RETENTION RATE AFTER 2 YEARS OF FOLLOW-UP IN PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM THE SPANISH REGISTRY BIOBADASER 2023 ·(unknown), Clementina López‐Medina, (unknown), Alejandro Escudero‐Contreras, R. Ortega Castro, (unknown), (unknown), (unknown), (unknown), (unknown), D. Ruiz-Montesinos, Manuel Pombo‐Suárez, Inmaculada Ros, Fernando Sánchez‐Alonso, Isabel Castrejón	0
4	Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases 2023 ·Advances in Rheumatology ·Manuel Pombo‐Suárez, Daniel Seoane‐Mato, Federico Díaz‐González, Fernando Sánchez‐Alonso, (unknown), Luis Cea‐Calvo, Isabel Castrejón	2
5	Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain 2021 ·Patient Preference and Adherence ·Manuel Pombo‐Suárez, José Ramón Maneiro, Juan J. Gómez‐Reino	16
6	Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry 2021 ·Clinical Rheumatology ·Manuel Pombo‐Suárez, Carlos Sánchez‐Piedra, (unknown), (unknown), Sara Manrique‐Arija, (unknown), (unknown), Cristina Campos, José Luís López-Campos, Javier del Pino‐Montes, (unknown), Luis Cea‐Calvo, Federico Díaz‐González, Juan J. Gómez‐Reino	13
7	Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry 2021 ·Musculoskeletal Care ·Manuel Pombo‐Suárez, Carlos Sánchez‐Piedra, (unknown), Cèsar Díaz‐Torné, Vega Jovaní, Luis Cea‐Calvo, Isabel Castrejón	1
8	Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety 2020 ·Pain ·John D. Markman, Robert Bolash, Timothy E. McAlindon, Alan Kivitz, Manuel Pombo‐Suárez, Seiji Ohtori, Frank W. Roemer, (unknown), Lars Viktrup, Candace Bramson, Christine R. West, Kenneth M. Verburg	38
9	The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs 2019 ·Pharmacological Research ·Manuel Pombo‐Suárez, Juan J. Gómez‐Reino	7
10	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis 2019 ·Seminars in Arthritis and Rheumatism ·Kim Lauper, Denis Mongin, Florenzo Iannone, Eirik Klami Kristianslund, Tore K Kvien, Dan Nordström, Karel Pavelká, Manuel Pombo‐Suárez, Žiga Rotar, María José Santos, Cătălin Codreanu, G. Lukina, Sara Gale, Markus R. John, (unknown), Delphine S. Courvoisier, Cem Gabay	18
11	OP0310 Prevalence of risk factors and cardiovascular events across psoriatic arthritis patients treated with biological therapy 2018 ·Annals of the Rheumatic Diseases ·(unknown), Carlos García‐Porrúa, (unknown), (unknown), (unknown), Manuel Pombo‐Suárez, J. Pinto-Tasende	1
12	Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries 2018 ·RMD Open ·Kim Lauper, Denis Mongin, Florenzo Iannone, Eirik Klami Kristianslund, Tore K Kvien, Dan Nordström, Karel Pavelká, Manuel Pombo‐Suárez, Žiga Rotar, María José Santos, Cătălin Codreanu, G. Lukina, Delphine S. Courvoisier, Cem Gabay	21
13	Genetic risk load and age at symptom onset of knee osteoarthritis 2011 ·Journal of Orthopaedic Research® ·Cristina Rodriguez‐Fontenla, (unknown), Manuel Calaza, Manuel Pombo‐Suárez, Juan J. Gómez‐Reino, Antonio González	5
14	Functional analysis of the osteoarthritis susceptibility–associated GDF5 regulatory polymorphism 2009 ·Arthritis & Rheumatism ·Rainer J. Egli, Lorraine Southam, James M. Wilkins, Inken Lorenzen, Manuel Pombo‐Suárez, Antonio González, Andrew Carr, Kay Chapman, John Loughlin	100
15	Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS‐5, in susceptibility to osteoarthritis 2008 ·Arthritis & Rheumatism ·Julio A. Rodriguez‐Lopez, Zehra Mustafa, Manuel Pombo‐Suárez, Κonstantinos Ν. Malizos, Ignacio Rego‐Pérez, Francisco J. Blanco, Aspasia Tsezou, John Loughlin, Juan J. Gómez‐Reino, Antonio González	34
16	Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage 2008 ·Annals of the Rheumatic Diseases ·Manuel Pombo‐Suárez, (unknown), Manuel Calaza, Juan J. Gómez‐Reino, Antonio González	37
17	Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage 2008 ·BMC Molecular Biology ·Manuel Pombo‐Suárez, Manuel Calaza, Juan J. Gómez‐Reino, Antonio González	72
18	An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage 2007 ·Human Molecular Genetics ·Lorraine Southam, Julio A. Rodriguez‐Lopez, James M. Wilkins, Manuel Pombo‐Suárez, Sarah Snelling, Juan J. Gómez‐Reino, Kay Chapman, Antonio González, John Loughlin	166
19	Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis 2007 ·Annals of the Rheumatic Diseases ·Julio A. Rodriguez‐Lopez, Manuel Pombo‐Suárez, (unknown), Juan J. Gómez‐Reino, Antonio González	44
20	Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians 2006 ·Arthritis Research & Therapy ·Julio A. Rodriguez‐Lopez, Manuel Pombo‐Suárez, (unknown), Juan J. Gómez‐Reino, Antonio González	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact